tiprankstipranks
Larimar Therapeutics Phase 2 Success in Friedreich’s Ataxia Trial
Company Announcements

Larimar Therapeutics Phase 2 Success in Friedreich’s Ataxia Trial

Larimar Therapeutics, Inc. (LRMR) has released an update.

On February 12, 2024, a company announced the successful completion of a significant Phase 2 trial for nomlabofusp, a treatment for Friedreich’s ataxia, through a press release and updated investors with presentations on their website. These materials are expected to be used in upcoming discussions with investors and analysts to showcase progress and potential.

For further insights into LRMR stock, check out TipRanks’ Stock Analysis page.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles